Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Second Division of Dermatology and Laboratory of Immunology, Istituto Dermopatico dell'Immacolata, IRCCS, Via dei Monti di Creta 104, 001 67 Rome, Italy. giro@idi.it
Tumor necrosis factor-a (TNFalpha) plays an important role in the initiation and persistence of inflammation in a variety of skin disorders. The availability of selective TNFalpha blockers has provided new therapeutic opportunities. TNFa inhibitors have been employed with success in treating psoriasis in controlled trials, although further studies are warranted to better define which subgroup of patients can benefit most from this treatment and modalities of combination therapy. In addition, an increasing number of case reports indicates that anti-TNFalpha agents are of value in the treatment of other skin diseases, such as pyoderma gangrenosum and Behcet's syndrome, and in the treatment of graft-versus-host disease.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on